

The key elements of the BAF are:

- A description of each Principal (strategic) Risk, that forms the basis of the Trust's risk framework (with corresponding corporate and operational risks defined at a Trust-wide and service level)
- Risk ratings current (residual), tolerable and target levels
- Clear identification of primary strategic threats and opportunities that are considered likely to increase or reduce the Principal Risk, within which they are expected to materialise
- A statement of risk appetite for each threat and opportunity, to be defined by the Lead Committee on behalf of the Board (**Averse** = aim to avoid the risk entirely; **Minimal** = insistence on low risk options; **Cautious** = preference for low risk options; **Open** = prepared to accept a higher level of residual risk than usual, in pursuit of potential benefits)
- Key elements of the risk treatment strategy identified for each threat and opportunity, each assigned to an executive lead and individually rated by the lead committee for the level of assurance they can take that the strategy will be effective in treating the risk (see below for key)
- Sources of assurance incorporate the three lines of defence: (1) Management (those responsible for the area reported on); (2) Risk and compliance functions (internal but independent of the area reported on); and (3) Independent assurance (Internal audit and other external assurance providers)
- Clearly identified gaps in the primary control framework, with details of planned responses each assigned to a member of the Senior Leadership Team (SLT) with agreed timescales

Key to lead committee assurance ratings:



Green = Positive assurance: the Committee is satisfied that there is reliable evidence of the appropriateness of the current risk treatment strategy in addressing the threat or opportunity

- no gaps in assurance or control AND current exposure risk rating = target

OR

gaps in control and assurance are being addressed



Amber = Inconclusive assurance: the Committee is not satisfied that there is sufficient evidence to be able to make a judgement as to the appropriateness of the current risk treatment strategy



Red = Negative assurance: the Committee is satisfied that there is sufficient reliable evidence that the current risk treatment strategy is not appropriate to the nature and/or scale of the threat or opportunity

This approach informs the agenda and regular management information received by the relevant lead committees, to enable them to make informed judgements as to the level of assurance that they can take and which can then be provided to the Board in relation to each Principal Risk and also to identify any further action required to improve the management of those risks.

This BAF includes the following Principal Risks (PRs) to the Trust's strategic priorities:

Reference	Principal risk	Lead committee	Initial date of assessment	Last reviewed	Target risk score C x L	Previous risk score (at previous review/update) C x L	Current risk score
PR1	Significant deterioration in standards of safety and care	Medical Director	01/04/2018	08/03/2021	4 x 2 = 8	4 x 5 = 20	4 x 5 = 20
PR2	Demand that overwhelms capacity	Chief Operating Officer	01/04/2018	08/03/2021	4 x 2 = 8	4 x 5 = 20	4 x 5 = 20
PR3	Critical shortage of workforce capacity and capability	Director of People	01/04/2018	27/04/2021	4 x 2 = 8	4 x 5 = 20	4 x 4 = 16
PR4	Failure to achieve the Trust's financial strategy	Chief Financial Officer	01/04/2018	27/04/2021	4 x 2 = 8	5 x 3 = 15	5 x 3 = 15
PR5	Inability to initiate and implement evidenced based improvement and innovation	Director of Culture & Improvement	17/03/2020	27/04/2021	3 x 2 = 6	3 x 3 = 9	3 x 3 = 9
PR6	Working more closely with local health and care partners does not fully deliver the required benefits	Chief Executive Officer	01/04/2020	13/04/2021	2 x 2 = 4	2 x 3 = 6	2 x 3 = 6
PR7	Major disruptive incident	Director of Corporate Affairs	01/04/2018	13/04/2021	4 x 1 = 4	4 x 3 = 12	4 x 2 = 8



Principal risk (what could prevent us achieving this strategic priority)	_	on in standards o	in standards of safe f safety and quality of pati mes	Strat	tegic priority	1. To provide outstanding care						
Lead Committee	Quality Risk rating Current exposure Tolerable Target Risk type Patient hard									25		
Executive lead	Medical Director	Consequence	4. High	4. High	4. High	Risk appetite	Minimal	15 -			——— Current risk level	
Initial date of assessment	01/04/2018	Likelihood	5. Very likely	3. Possible	2. Unlikely			10 - 5 -			Tolerable risk	
Last reviewed	08/03/2021	Risk rating	20. Significant	12. High	8. Medium			0 -	-20 -20 -20 -20 -20 -20 -20 -20 -20 -20	Aug-20 Sep-20 Oct-20 Vov-20 Jan-21 Feb-21	level	
Last changed	08/03/2021								Apr May Jun	Aug Sep Oct Nov Dec Jan Feb		

	1					Common of the co		Construction of the state of th	
trategic threat rhat might cause this to happen)	assist us in managir the threat)	stems & processes do we ng the risk and reducing t	he likelihood/ impact of	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are pla		Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
A widespread loss of organisational focus on patient safety and quality of care leading to increased incidence of avoidable narm, exposure to 'Never events', higher than expected mortality, and ignificant reduction in patient satisfaction	governance service level: Monthly m Cabinet (Q CQC regist: Advancing group Nursing an Clinical polic supporting description of the Clinical audit arrangement Clinical staff training, registeric level:	neeting of Quality & (ASC) with work progration regulations Quality Programme and Midwifery and AH (Sies, procedures, guide) to programme & month of the programme & month	Assurance Safety gramme aligned to and AQP oversight  P Business meeting delines, pathways, systems altoring ion, mandatory tion	Intranet currently contains some out of date clinical information that may still be accessible	Intranet documents review SLT Lead: Head of Communications Timescale: end March 2021	Management: Learning from deaths Report Quarterly Strategic Priority Report to Board Risk Committee bi-annually; Guardian of Sa Board qrtly  Quality and Governance Reporting Pathway Safety Cabinet →Quality Committee Reports include:  DPR Report to QASC monthly and QC bi- QASC assurance report to QC bi-monthing Patient Safety Culture (PSC) programming EoLC Annual Report to QC Safeguarding Annual Report to QC CYPP report to QC quarterly Medical Education update report to QC Medicines Optimisation Annual Report  Medicines Optimisation Annual Report	; Divisional risk reports to fe Working report to  7; Quality Assurance and  8i-monthly 1ly 1e  C-Jul-'19		
	wards & dep monitored b Ward assura programme Nursing & M AHP Strategy	partments (Nursing s by Chief Nurse) ance/ metrics and ac lidwifery Strategy	afeguards creditation			- Senior Leadership Walkarounds weekly Outputs from internal reviews against Exterincluding; - HSIB Thromboembolic Maternity Repo - National Audit for Care of end of Life (Section - Ockenden Report (Dec 2020)  Risk & compliance: Quality Dashboard and Quality Account Report Qtrly to QASC and Cereport to QASC monthly; CQC report to QC Risk Report to RC monthly	rnal National Reports  rt (Oct 2020) Sep 2020)  SOF to QASC Monthly; QC; SI & Duty of Candour	None	Positiv
						Independent assurance: CQC Inspection Re CQC Insight tool to QPSC monthly; CQC Rati Transfer of Handover assurance report QC S newborn screening peer review QC Nov'18 Audit to PSQG 2018, ICNARC Quarterly Report 2018; EoLC Audit 2018; PHQA visit for Smok Inpatient Survey 2017; Maternity Inpatient	ing and oversight; IA (360) Sep '18; Antenatal & ; Sherwood Birthing Unit ort; SHOT report to QPSC se-free Life; Audit		



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
			within tolerable range?)	Tool to QPSC monthly and QC bi-monthly; GMC Feedback 2018; NNAP Audit 2018; Care Quality Commission / External Regulation Report to QC Mar '19; Medicines Optimisation Report to QC Mar '19; Care Quality Commission / External Regulation Report to QC Mar '19; Medicines Optimisation Report to QC Mar '19		
				Screening Quality Assurance Services assessments and reports of:  - Antenatal and New-born screening  - Breast Cancer Screening Services  - Bowel Cancer Screening Services  - Cervical Screening Services		
				External Accreditation/Regulation annual assessments and reports of;  - Pathology (UKAS)  - Endoscopy Services (JAG)  - Medical Equipment and Medical Devices (BSI)  - Blood Transfusion Annual Compliance Report (MHRA)		
An outbreak of infectious disease (such as pandemic influenza; Coronavirus; norovirus; infections resistant to antibiotics) that forces closure of one or more areas of the hospital	<ul> <li>Infection prevention &amp; control (IPC) programme Policies/ Procedures; Staff training; Environmental cleaning audits</li> <li>PFI arrangements for cleaning services</li> <li>Root Cause Analysis and Root Cause Analysis Group</li> <li>Reports from Public Health England received and acted upon</li> <li>Infection control annual plan developed in line with the Hygiene Code</li> <li>Influenza and Covid vaccination programmes</li> <li>Public communications re: norovirus and infectious diseases</li> <li>Coronavirus identification and management process</li> </ul>	None	N/A	Management: Divisional reports to IPC Committee (every 6 weeks); IPC Annual Report to QC and Board; Water Safety Group; IPC BAF report to QASC and QC Risk & compliance: IPC Committee report to QPSC qtrly; SOF Performance Report to Board monthly; IPC Clinical audits in IPCC report to QPSC qtrly Independent assurance: Internal audit plan; CQC Rating Good with Outstanding for Care Aug '18 May '20; PLACE Assessment and Scores Estates Governance bi-monthly; Public Health England attendance at IPC Committee; Influenza vaccination cumulative number of staff vaccinated; HSE visit Dec '20 – no concerns highlighted IPC BAF Peer Review by Medway Trust HSE External assessment and report HSIB IPC assessment and report	Learning from the impact on activity, patient safety and staffing due to COVID-19 wave 1  Constraints of critical care capacity and PPE availability dependent on the size of future waves and restoration activity  Business case to enhance oxygen capacity/flow has been delivered — awaiting further instruction from NHSE/I	Inconclusive



Principal risk (what could prevent us achieving this strategic priority)	PR 2: Demand that ov Demand for services that ov care	<u>-</u>	oration in the quality,		Stra	tegic priority	1. To provide outstanding care				
Lead Committee	Quality	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient harm	25			
<b>Executive lead</b>	Chief Operating Officer	Consequence	4. High	4. High	4. High	Risk appetite	Minimal	20 15			—— Current risk level
Initial date of assessment	01/04/2018	Likelihood	5. Very likely	4. Somewhat likely	2. Unlikely			10 5			Tolerable risk level
Last reviewed	08/03/2021	Risk rating	20. Significant	16. Significant	8. Medium			0	20 20 20 20 20 20 20 20 20 20 20 20 20 2	20 20 20 20 20 20 20 20 20 20 20 20 20 2	······ Target risk level
Last changed	08/03/2021								Apr- May- Jun-	Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21	

Last changed 08/03/2	021			4 5 1 4 8 0		
Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
Threat: Growth in demand for care caused by an ageing population (forecast annual increase in emergency demand of 4-5% per annum); reduced social care funding and increased acuity leading to more admissions and longer length of stay, or a reduction in capacity to meet current and future demand due to the impact of COVID-19	<ul> <li>Emergency admission avoidance schemes across the system</li> <li>Single streaming process for ED &amp; Primary Care – regular meetings with NEMs</li> <li>Trust and System escalation process</li> <li>Cancer Improvement plan</li> <li>Trust leadership of and attendance at A&amp;E Board</li> <li>Patient pathway, some of which are joint with NUH</li> <li>Inter-professional standards across the Trust to ensure turnaround times such as diagnostics are completed within 1 day</li> <li>Proactive system leadership engagement from SFH into Better Together Alliance Delivery Board</li> <li>Patient Flow Programme</li> <li>SFH internal Winter capacity plan &amp; Mid Notts system capacity plan</li> <li>Referral management systems shared between primary and secondary care</li> <li>MSK pathways</li> <li>COVID-19 Incident planning and governance process</li> <li>Some cancer services maintained during COVID-19</li> <li>Risk assessments to prioritise individual patients</li> <li>Recovery Committee</li> </ul>	Robust delivery of the demand management schemes across the system	On-going discussions across ICS and specifically with NUH to describe future service delivery. Continued development of ICS clinical service strategy, Tomorrow's NUH Refresh NUH/SFH Exec to Exec forum 6-monthly progress updates to Board SLT Lead: Medical Director Timescale: end March 2021	Management: Performance management reporting arrangements between Divisions, Service Lines and Executive Team; Winter Plan to Board Oct '20; Exec to Exec meetings; Cancer 62 day improvement plan to Board; Planning documents for 19/20 to identify clear demand and capacity gaps/bridges; Identifying and capturing Potential Harm Resultant from COVID-19 Pandemic report to Board Jun '20; COVID-19 Recovery Plan to Board Sep '20; Elective Services Report to Recovery Committee monthly Risk & compliance: Divisional risk reports to Risk Committee bi-annually; Significant Risk Report to RC monthly; Single Oversight Framework Integrated Monthly Performance Report to Board; Incident Control Team governance structure to TMT Mar '20 Independent assurance: IA review of outpatient Demand and capacity modelling Jul '18; Regulatory Framework — Performance Standards (Emergency Readmissions Indicator) Follow - Up Sep '18; NHSI Intensive Support Team review of cancer processes May '20		Positive
Threat & Opportunity: Operational failure of General Practice to cope with demand resulting in even higher demand for secondary care as the 'provider of last resort'	<ul> <li>Visibility on the CCG risk register/BAF entry relating to operational failure of General Practice</li> <li>Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development</li> <li>Weekly Executive meeting with the CCGs</li> <li>Weekly Mid Notts Network Calls</li> </ul>			Management: Routine mechanism for sharing of CCG and SFH risk registers – particularly with regard to risks for primary care staffing and demand Independent assurance: 'Drivers of demand' discussed at Board Aug '19	Lack of recent GP vacancy rates data received from Primary Care  Pursue current GP vacancy data SLT Lead: COO Timescale: end January 2021 March '21	Inconclusive
Threat & Opportunity: Drop in operational performance of neighbouring providers that creates a shift in the flow of patients and referrals to SFH	<ul> <li>Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development</li> <li>Horizon scanning with neighbour organisations via meetings between relevant Executive Directors</li> <li>Weekly management meeting with the Service Director from Notts HC</li> <li>Bilateral work – Strategic Partnership forum</li> </ul>	None	N/A	Risk and compliance: Divisional NUH/SFH strategic partnership forum minutes and action log; NUH service support to SFH paper to Executive Team	Lack of control over the flow of patients from the surrounding area	Inconclusive



Principal risk (what could prevent us achieving this strategic priority)	PR 3: Critical shortage of v A shortage of workforce capacity have an adverse impact on patier	and capability re	•		Strategic priority	3: To maximise the potential of our workforce			
Lead Committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	25	
<b>Executive lead</b>	Executive Director of People	Consequence	4. High	4. High	4. High	Risk appetite	Cautious	15	— Current risk level
Initial date of assessment	01/04/2018	Likelihood	5. Very likely 4. Somewhat likely	4. Somewhat likely	2. Unlikely			10 5	Tolerable risk level
Last reviewed	27/04/2021	Risk rating	20. 16. Significant	16. Significant	8. Medium			0 0 50 70 8	Target risk level
Last changed	27/04/2021							May- nul- lut	Aug20 Sep-20 Oct-20 Dec-20 Jan-21 Mar-21 Apr-21

Last Changeu	27/04/2021										
Strategic threat (what might cause this t				<b>ready</b> have in place to assist us ir f the threat)	n managing ( v r t	Gaps in control Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	(Evidence that	assurance (and date) the controls/ systems which we are e on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Inability to staff due to demog (including a signific external factors and circumstances) and attitudes to careers employment marker reduced availability competition) result workforce gaps in services	raphic changes ant impact of d/or unforeseen I shifting cultural s, combined with et factors (such as and increased cing in critical	<ul> <li>People and Inc</li> <li>Culture and Im</li> <li>Medical and Ni</li> <li>Activity, Workf</li> <li>2 year workfor review process winter capacity</li> <li>Vacancy manage</li> <li>TRAC system for used to plan st</li> <li>Defined safe medepartments /</li> <li>Temporary star authorisation leducation part</li> <li>Director of People Workforce plan</li> <li>Communication and provision of Pensions restree</li> </ul>	provement Cabine force force and Financial ce plan supported lites (consultant job plans) gement and recruit for recruitment; e-Reaff utilisation fedical & nurse staff Safe Staffing Stand ffing approval and revels for reships ople attendance at laning for system were	plan by Workforce Planning Gro blanning; workforce model ment systems and process bestering systems and proce fing levels for all wards and ard Operating Procedure recruitment processes with People and Culture Board ork stream HMRC taxation rules on p	oup and elling; ses edures d h defined	ack of Divisional ownership and understanding of their workforce issues	Implementation of the People, Culture and Improvement Strategy (People and Inclusion) SLT Lead: Executive Director of People Timescale: April 2021complete - submitted to P,C&I Committee for approval  Deliver the People, Culture and Improvement Strategy (People and Inclusion) SLT Lead: Executive Director of People Timescale: March 2022  Increase staffing to meet the Phase 3 Activity Plan SLT Lead: Executive Director of People Timescale: March 2021complete	2018/20; Que to Board; Al Nursing and staffing reports on Four Improvement Imp	nt: Nursing & Midwifery Strategy uarterly Strategic Priority Report HP Strategy to Board Sep '19; I Midwifery and AHP six monthly ort – Nov 20; Workforce and OD ate quarterly; Quarterly Assurance People & Inclusion and Culture & nt to People Culture and nt Committee; People Culture and nt: COVID-19 Update May '20; t & Retention report monthly mpliance: Risk Committee isk report Monthly; HR & planning report Risk Committee; force Indicators (Monthly); Bank report (monthly); Guardian of safe port to Board Nov '20 nt assurance: Well-led report CQC; resources report; IA Recruitment n report Jan '19 – Significant EU Exit Risk System Overview – n and Nottinghamshire System Dec ployment Checks internal audit 21 – significant assurance; HSJ acute Trust of the Year 2021	Staff becoming infected, leading to increased sickness absence  Staff working in unfamiliar roles  Staff mental health as a result of psychological trauma	Inconclusiv



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: A significant loss of workforce productivity arising from a short-term reduction in staff availability or a reduction in effort above and beyond contractual requirements amongst a substantial proportion of the workforce and/or loss of experienced colleagues from the service, or caused by other factors such as poor job satisfaction, lack of opportunities for personal development, on-going pay restraint, workforce fatigue or wellbeing issues, or failure to achieve consistent values and behaviours in line with desired culture This could also lead to lack of engagement with patients, resulting in failure to address patient empowerment and self-help and failure to work across the system to empower patients and carers to enable personalised patient centred care	<ul> <li>People Culture and Improvement Strategy</li> <li>People and Inclusion Cabinet</li> <li>Culture and Improvement Cabinet</li> <li>Chief Executive's blog / Staff Communication bulletin</li> <li>Engagement events with Staff Networks (BAME, LGBT, WAND, Time to Change)</li> <li>Schwartz rounds</li> <li>Learning from COVID</li> <li>Staff morale identified as 'profile risk' in Divisional risk registers</li> <li>Star of the month/ milestone events</li> <li>Divisional action plans from staff survey</li> <li>Policies (inc. staff development; appraisal process; sickness and relationships at work policy)</li> <li>Just and restorative culture</li> <li>Influenza vaccination programme</li> <li>COVID-19 vaccination programme</li> <li>Staff wellbeing drop-in sessions</li> <li>Staff counselling / Occ Health support</li> <li>Enhanced equality, diversity and inclusion focus on workforce demographics</li> <li>Freedom to Speak Up Guardian and champion networks</li> <li>Emergency Planning, Resilience &amp; Response (EPRR) arrangements for temporary loss of essential staffing (including industrial action and extreme weather event)</li> </ul>	Inequalities in staff inclusivity and wellbeing across protected characteristics groups	Implementation of the People, Culture and Improvement Strategy (Culture and Improvement) SLT Lead: Executive Director of People Timescale: April 2021 complete — submitted to P,C&I Committee for approval  Deliver the People, Culture and Improvement Strategy (Culture and Improvement) SLT Lead: Executive Director of People Timescale: March 2022  Completion and delivery of WRES and WDES action plans SLT Lead: Executive Director of People Timescale: March 2021complete  Review and refine the current health and wellbeing offer SLT Lead: Executive Director of People Timescale: April 2021complete  Deliver the Equality, Diversity and Inclusivity Strategy SLT Lead: Executive Director of People Timescale: March 2022	Management: Staff survey, action plan and annual report to Board Oct '20; Diversity & Inclusion Annual report Jun '20; WRES and WDES report to Board Jun '20; Combined assurance report addressing; D&I, Violence & Aggression, Restraints Oct 20 Board; Quarterly Assurance reports on People & Inclusion and Culture & Improvement to People Culture and Improvement Committee; People Culture and Improvement: COVID-19 Update May '20; Equality & Diversity presentation to Board Aug '20; Business Continuity exercises — post exercise reports through Resilience Assurance Committee (rolling program)  Risk and compliance: EPRR Report (biannually); Freedom to speak up self-review BoardOct '20; Freedom to Speak Up Guardian report quarterly; Guardian of Safe Working report to Board Dec '20; Gender Pay Gap report to Board Mar '20; TRAC Performance Report to P, OD&C quarterly; Interim NHS People Plan self-assessment to People Culture & Inclusion Sep '20; Significant Risk Report to RC monthly; Gender Pay Gap report to Board Apr '21 Independent assurance: National Staff Survey Nov '19Mar '21; SFFT/Pulse surveys (Quarterly); Well-led report CQC; Confirm and Challenge by NHS England Regional team and CCGs Sep '18; Internal Audit Business Continuity and Emergency Planning Sep '18	Reduction in available staff due to COVID-19, e.g. shielding of vulnerable staff groups and social distancing; redeployment to the vaccination programme  Reduction in effort above and beyond contractual requirements due to COVID-19 service restrictions  Reluctance of some staff members to return to work due to COVID-19-associated health concerns  Restrictions to deployment of key staff due to reduced availability of Mandatory and Statutory Training, and the consequential expiry of certification	Inconclusive



Principal risk (what could prevent us achieving this strategic priority)	PR 4: Failure to achieve the Trust's financial strategy Failure to achieve agreed trajectories resulting in regulatory action							Strategic priority	5: To achieve better value	
Lead Committee	Finance	Risk rating	Current exposure	Tolerable	Target	Risk type	Regulatory action	20		
<b>Executive lead</b>	Chief Financial Officer	Consequence	5. Very high	4. High	4. High	Risk appetite	Cautious	15		—— Current risk level
Initial date of assessment	01/04/2018	Likelihood	3. Possible	3. Possible	2. Unlikely			5		Tolerable risk level
Last reviewed	27/04/2021	Risk rating	15. Significant	12. High	8. Medium			0 0 0 0	20	····· Target risk level
Last changed	27/04/2021							May	Aug-20 Sep-20 Oct-20 Nov-20 Jan-21 Feb-21 Mar-21	

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps	Assurance rating
Threat: A reduction in funding or change in financial trajectory or unexpected event resulting in an increased Financial Improvement Plan (FIP) requirement to reduce the scale of the financial deficit, without having an adverse impact on quality and safety	<ul> <li>5 year long term financial model</li> <li>Working capital support through agreed loan arrangements</li> <li>Annual plan, including control total consideration; reduction of underlying financial deficit and unwinding of the PFI benefit by £0.5m annually</li> <li>Engagement with the Better Together alliance programme</li> <li>Transformation and Efficiency CabinetFIP Board, FIP planning processes and PMO coordination of delivery</li> <li>Delivery of budget holder training workshops and enhancements to financial reporting</li> <li>A full 'wash up' of portfolio planning, delivery and engagement conducted; recovery plan in place, Board approved &amp; governance in place</li> <li>Medical Pay Task Force action plan in place</li> <li>Close working with ICS partners to identify system-wide planning, transformation and cost reductions</li> <li>Executive oversight of commitments</li> <li>All costs and required cash associated with COVID-19 funded in full for period 1/4/20 to 30/9/20</li> <li>2021/22 Planning guidance confirms continuation of 20/21 funding regime for H1</li> </ul>	No long term commitment received for liquidity / cash support  Lack of identification of opportunities for recurrent delivery of FIP  Lack of clarity on the financial regime for 21/22 H2  £9m deficit forecast in M7-12 resource envelope	Full receipt of required cash (FRF) following delivery of NHSI required future trajectories  SLT Lead: Chief Financial Officer  Timescale: 2021/22 H2 plan submission date (TBC by NHSI)  Full review of ability to improve recurrent delivery of FIP within financial planning for 2021/22  SLT Lead: Director of Culture and Improvement  Timescale: 2021/22 H2 plan submission date (TBC by NHSI)  H1 and H2 budget setting process for 2021/22 to include enhanced confirm and challenge  SLT Lead: Chief Financial Officer  Timescale: 2021/22 H2 plan submission date (TBC by NHSI)  Monthly reviews of forecasts by CFO, monitoring and reporting of delivery of forecast (not plan), no reinvestment of favourable variance to forecast, adverse variances to be recovered  SLT Lead: Chief Financial Officer  Timescale: October 2020 to March 2021 — complete  Weekly review meetings with NHSI to explain the 2019/20 impact on current £9m deficit  SLT Lead: Chief Financial Officer  Timescale: October 2020 to March 2021 — complete	Management: Delivery of improved 20/21 financial position; CFO's Financial Reports & FIP Summary (Monthly); Quarterly Strategic Priority Report to Board; Alliance Progress Report & STP FIP (at each Finance Committee meeting); Investment governance work programme; Divisional risk reports to Risk Committee bi-annually Risk and compliance: Risk Committee significant risk report Monthly; Independent assurance: Internal Audit Report FIP/ QIPP (Jul '18); EY Financial Recovery Plan; all costs associated with COVID-19 reimbursed in full to 30/9/20	Awaiting H2 2021/22 NHSI/E planning guidance	Inconclusiv
<b>Threat:</b> ICS system deficit results in a negative financial impact to the Trust	<ul> <li>Full participation in ICS planning</li> <li>SFH plan consistency with ICS plan</li> <li>ICS DoFs Group</li> <li>ICS Strategy and Delivery Group</li> <li>ICS Planning Group</li> <li>ICS Financial Sustainability Group</li> </ul>	ICS underlying financial deficit	Full participation in the development of the ICS Financial Strategy and aligned payment mechanisms SLT Lead: Chief Financial Officer Timescale: 31/3/20212021/22 H2 plan submission date (TBC by NHSI)	Risk and compliance: ICS financial reports to Finance Committee; ICS Board updates to SFH Trust Board	Awaiting H2 2021/22 NHSI/E planning guidance	Inconclusive



Principal risk (what could prevent us achieving this strategic priority)	•	PR 5: Inability to initiate and implement evidence-based improvement and innovation ack of support, capability and agility to optimise strategic and operational opportunities to improve patient care							egic priority	4: To continuously learn and in	mprove
Lead Committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient Harm	10			
Executive lead	Director of Culture & Improvement	Consequence	3. Moderate	3. Moderate	3. Moderate	Risk appetite	Cautious	8 - 6 -	*********		Current risk level
Initial date of assessment	17/03/2020	Likelihood	3. Possible	3. Possible	2. Unlikely			4 -			Tolerable risk level
Last reviewed	27/04/2021	Risk rating	9. Medium	9. Medium	6. Low			0 -	02 02 02	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	······ Target risk level
Last changed	27/04/2021								May-2 Jun-2 Jul-2 Aug-2	Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21	

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Lack of understanding and agility resulting in reduced efficiency and effectiveness around how we provide care for patients	<ul> <li>Digital Strategy</li> <li>Improvement Strategy</li> <li>People, Culture &amp; Improvement Committee</li> <li>Leadership development programmes</li> <li>Talent management map</li> <li>Programme Management Office</li> <li>Culture &amp; Improvement Cabinet</li> <li>Transformation Cabinet</li> <li>Ideas generator platform</li> </ul>		Establish an ideas generator platform SLT Lead: Director of Culture and Improvement Timescale: end March 2021complete  Introduction of a newly designed QI training offer SLT Lead: Director of Culture and Improvement Timescale: May 2021	Management: Monthly FIP/Transformation and Efficiency report to FC; Clinical Audit & Improvement report to QASC quarterly; Culture & Improvement Assurance Report to PC&IC bimonthly  Risk and compliance: SOF Culture and Improvement indicators; SFH breakthrough objectives to Board quarterly  Independent assurance: none currently in place	Delays in <u>training</u> , planned improvement and innovation programmes due to COVID-19	
			Proposal for Continuous Improvement in SFH SLT Lead: Director of Culture and Improvement Timescale: May 2021			Positive
			Establishment of an Innovation Hub SLT Lead: Director of Culture and Improvement Timescale: June 2021			
			Recruit a Chief Information Officer SLT Lead: Medical Director Timescale: August 2021			



Principal risk (what could prevent us achieving this strategic priority)	PR 6: Working more closely with local health and care partners does not fully deliver the required benefits  Influencing the wider determinants of health and improving our collective financial position requires close partnership working. This may be difficult because of differences in governance, objectives and appetite for and ability to change.							Strategic priority	2: To promote and support heal	th and wellbeing	
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	10			
<b>Executive lead</b>	Chief Executive Officer	Consequence	2. Low	2. Low	2. Low	Risk appetite	Cautious	6 — Current ris			
Initial date of assessment	01/04/2020	Likelihood	3. Possible	4. Possible	2. Unlikely			4 2		Tolerable risk level	
Last reviewed	13/04/2021	Risk rating	6. Low	8. Medium	4. Low			0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	22 20 20 20 21 21 21 21 21 21 21 21 21 21 21 21 21	····· Target risk level	
Last changed	09/03/2021							May- Jun.	Aug20 Sep-20 Oct-20 Nov-20 Jan-21 Feb-21 Apr-21		

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Conflicting priorities, financial pressures (system financial plan misalignment) and/or ineffective governance resulting in a breakdown of relationships amongst ICS and ICP partners and an inability to influence further integration of services across acute, mental, primary and social care	<ul> <li>Mid-Nottinghamshire Integrated Care Partnership Board</li> <li>Mid-Nottinghamshire ICP Executive formed May 2020</li> <li>Mid-Nottinghamshire ICP breakthrough objectives signed off July 2020</li> <li>Nottingham and Nottinghamshire Integrated Care System Board</li> <li>Continued engagement with ICP and ICS planning and governance arrangements</li> <li>Quarterly ICS performance review with NHSI</li> <li>Joint development of plans at ICS level</li> <li>Finance Directors Group</li> <li>ICS Planning Group</li> <li>Alignment of Trust, ICS and ICP plans</li> <li>Trust CFO role as ICS Finance Director</li> <li>Independent chair for ICP</li> </ul>	Exec to Exec meetings with mid-Nottinghamshire CCG and Nottinghamshire Healthcare have been paused – attempting to restart	ICS governance review to include:  Roles and responsibilities of the ICS Board Governance manual New ICS Chair to be appointed and starts in Feb 2021 started in February 2021 SLT Lead: Chief Executive Officer Timescale: under review December 2020 June 2021  Restore Exec to Exec meetings with mid-Nottinghamshire CCG and Nottinghamshire Healthcare SLT Lead: Chief Executive Officer Timescale: Will review once we move out of wave twoat an appropriate time — CEO meetings and other exec to exec meetings continue Board to Board with Notts Healthcare agreed for early April 2021. CEO and Chair of NUH, NHC and SFH met in February.	Management: Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Nottingham and Nottinghamshire ICS Leadership Board Summary Briefing to Board; Planning Update to Board Risk & compliance: Significant Risk Report to RC monthly Independent assurance: 360 Assurance review of SFH readiness to play a full part in the ICS – Significant Assurance	Delay in delivering the benefits of system working due to the impact of COVID-19	Inconclusive
Threat and Opportunity: Clinical service strategies and/or commissioning intentions that do not sufficiently anticipate evolving healthcare needs of the local population and/or reduce health inequalities	<ul> <li>Continued engagement with commissioners and ICS developments in clinical service strategies focused on prevention</li> <li>Partnership working at a more local level, including active participation in the mid-Nottinghamshire ICP</li> <li>Clinical Services Strategy - 5 of 20 services complete</li> </ul>	Insufficient granularity of plans to meet the needs of the population and the statutory obligations of each individual organisation	Development of a co-produced clinical services strategy for the ICS footprint – 2 <sup>nd</sup> set of 5 services <b>SLT Lead:</b> Medical Director 5 of 20 services complete as at October 2019 <b>Timescale:</b> end December 2020June 2021	Management: Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Planning Update to Board Independent assurance: none currently in place	Delay in delivering the benefits of system working due to the impact of COVID-19	Inconclusive



Principal risk (what could prevent us achieving this strategic priority)	PR 7: Major disruptive incident  A major incident resulting in temporary hospital closure or a prolonged disruption to the continuity of core services across the Trust, which also impacts significantly on the local health service community								tegic priority 1:	To provide outstanding care	
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	15 -			
<b>Executive lead</b>	Director of Corporate Affairs	Consequence	4. High	4. High	4. High	Risk appetite	Cautious	10 -			——Current risk level
Initial date of assessment	01/04/2018	Likelihood	3. Possible 2. Unlikely	3. Possible	1. Very unlikely			5 -	•••••		Tolerable risk level
Last reviewed	13/04/2021	Risk rating	12. High 8. Medium	12. High	4. Low			0 -	20 -20 -20 -20 -20 -20 -20 -20 -20 -20 -	Sep-20 Oct-20 Nov-20 Jan-21 Feb-21 Apr-21	····· Target risk level
Last changed	13/04/2021								May Jun Aug	Sep Oct Nov Dec Jan Feb Rar	

Last changed	13/04/2021						May-20 Jun-20 Jul-20 Aug-20 Sep-20	Oct-2( Nov-2( Dec-2( Jan-2: Feb-21  Mar-2: Apr-2:		
		sses do we <b>already</b> have in g the likelihood/ impact of t		Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to im control (are further cont order to reduce tolerable range?	rols possible in risk exposure within	Sources of assurance (ar (Evidence that the controls/ sy reliance on are effective)		Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: A large scale attack that sShuts dethe IT network due to large-scale cyber-att system failure that a severely limits the availability of essent information for a prolonged period	NHIS Cyber Security St  O a  Cyber Security Prograr  Project Group and wor  Cyber news – circulate  Network accounts che	rategy nme Board & Cyber Se k plan d to all NHIS partners cked after 50 days of i if not used place cises carried out by 36	ecurity  nactivity –  0 Assurance				submission to Board Mai Hygiene Report to Cyber NHIS report to Risk Com- annual report to Risk Com- and COVID-19 Report to Independent assurance: Security Governance Rep Assurance; 360 Assurance Protection Toolkit Indeports '20 – High confidence in Information Security Ma TIAN / 360 Assurance Cy	r Security Board monthly; mittee quarterly; IG Bi- mmittee; Cyber Security Board May '20 : 360 Assurance Cyber port Jan '19 – Significant ce Data Security and endent Assessment Mar submission; ISO 27001 inagement Certification; ther Security Survey - The ne NHS Dec '20; CCG Cyber	Insufficient assurance regarding governance and interface with NHIS  360 Assurance internal audit of governance and interface – ToRs agreed final report in draft  SLT Lead: Medical Director  Timescale: January February 2021	Positive
Threat: A critical infrastructure failure caused by an interruto the supply of one more utilities (electricias, water), an uncontrolled fire or security incident or of the built environmentat renders a signif proportion of the estinaccessible or unserviceable, disruservices for a prolon period	ption or city,   PFI Contract and Estate PFI Partners  in Fire Safety Strategy NHS Supply Chain resil Emergency Prepared arrangements at regio levels  in Operational strategies incident (e.g. industria disease; power failure; evacuation; CBRNe)	es Governance arrange ience planning ess, Resilience & Responal, Trust, division and & plans for specific ty l action; fuel shortage, severe winter weather mmand structure for remergency Planning & second in the	onse (EPRR) I service  pes of major ; pandemic er;  major security	Operational resilience of the Central Sterile Services Department (CSSD)	the preferred provision opt Executive tea SLT Lead: Div Manager - Su Timescale: er February 202  Surgery divisithe CSSD servicase to the Executive tea provision of the Executive tea prov	m isional General rgery nd January 1 — complete on to present vice business kecutive team isional General rgery	plc monthly performance Annual Report; Condition Water System) update to '19Water Safety Update Jul '20 Risk & compliance: Monto Risk Committee Independent assurance: Model to RC Dec '18; EPI standards compliance ra Assurance; Water Safety	n of retained estate (CCU or Risk Committee Jan Report to Risk Committee Inthly Significant Risk Report  Premises Assurance RR Report; EPRR Core Outing (Oct '19) – Substantial or report (WSP) to Joint Preport (WSP) report – hard FM	Insufficient assurance of hard and soft FM contractor performance  Monitor hard and soft FM performance and provide periodic assurance reports  SLT Lead: Associate Director of Estates & Facilities  Timescale: up to end March 2021	Positive



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: A critical supply chain failure that severely restricts the availability of essential goods, medicines or services for a prolonged period	<ul> <li>NHS Supply Chain resilience planning Business Continuity Management System &amp; Core standards</li> <li>CAS alert system – Disruption in supply alerts</li> <li>Major incident plan in place</li> <li>PPE Strategy</li> <li>PPE Winter Forecast 2020/21</li> <li>EU Exit Preparation Meetings</li> <li>COVID-19 Pandemic Surge Plan</li> <li>Procurement Influenza Pandemic Business Continuity Plan</li> <li>Interim provision for transmission of personal data to the United Kingdom clause within the EU Exit agreement</li> </ul>	None	N/A	Management: Procurement Annual Report to Audit & Assurance Committee; Oxygen Supply Assurance report to Incident Control Team Apr '20; COVID-19 Governance Assurance Report to Board May '20 Independent assurance: Internal Audit Business Continuity and Emergency Planning Sep '18 – Significant Assurance; 2019/20 Counter Fraud, Bribery and Corruption Annual Report; EU Exit Risk System Overview – Nottingham and Nottinghamshire System Dec '20	Security of supplies due to:  - Unknown impact of Brexit on critical items including medicines  - Potential ban on exports to the UK from China	Positive